QDEL
NASDAQQuidelOrtho Corporation
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
Price$14.46+0.23 (+1.65%)
01:30 PM07:45 PM
News · 26 weeks75-21%
2025-12-142026-06-07
Mix4390d
- Insider20(47%)
- Other13(30%)
- SEC Filings5(12%)
- Leadership2(5%)
- Earnings2(5%)
- M&A1(2%)
Latest news
25 items- INSIDERDirector Strobeck Matthew was granted 6,829 shares, increasing direct ownership by 25% to 34,604 units (SEC Form 4)4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERDirector Widder Kenneth J was granted 6,829 shares, increasing direct ownership by 18% to 43,890 units (SEC Form 4)4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERDirector Polan Mary Lake Ph D was granted 6,829 shares, increasing direct ownership by 54% to 19,469 units (SEC Form 4)4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERDirector Buechler Kenneth F was granted 6,829 shares, increasing direct ownership by 7% to 108,750 units (SEC Form 4)4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERDirector Chiminski John R was granted 6,829 shares, increasing direct ownership by 271% to 9,352 units (SEC Form 4)4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERDirector Huennekens R Scott was granted 6,829 shares, increasing direct ownership by 271% to 9,352 units (SEC Form 4)4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERDirector Wilkins Joseph D Jr. was granted 6,829 shares, increasing direct ownership by 58% to 18,705 units (SEC Form 4)4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERDirector Rhoads Ann D was granted 6,829 shares, increasing direct ownership by 42% to 23,257 units (SEC Form 4)4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERDirector Michael Edward L. was granted 6,829 shares, increasing direct ownership by 32% to 28,181 units (SEC Form 4)4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERDirector Dilsaver Evelyn S was granted 6,829 shares, increasing direct ownership by 64% to 17,453 units (SEC Form 4)4 - QuidelOrtho Corp (0001906324) (Issuer)
- PRQuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized PregnanciesSAN DIEGO, June 2, 2026 /PRNewswire/ -- QuidelOrtho, a global leader in diagnostic innovation, and the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians managing maternal alloimmunization, announced a new collaboration focused on improving prenatal care through education, early testing and stronger connections between laboratory providers, clinicians and patients. Maternal red blood cell alloimmunization is a serious, often misunderstood condition that can pose significant risks to the child during pregnancy. Red cell antibodies can cross the placenta and destroy fetal and neonatal red blood cell
- INSIDERDirector Rhoads Ann D was granted 1,407 shares, increasing direct ownership by 9% to 16,428 units (SEC Form 4)4 - QuidelOrtho Corp (0001906324) (Issuer)
- PRWhen Blood Compatibility Becomes a Pregnancy RiskSAN DIEGO, May 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL), a global leader of in vitro diagnostics, has released episode 58 of its Science Bytes podcast, focusing on hemolytic disease of the fetus and newborn (HDFN) – a serious but often underrecognized condition driven by maternal alloimmunization. Hosted by Michelle Mullens, Global Product Manager of Portfolio Solutions for Transfusion Medicine at QuidelOrtho, the episode features Bethany Weathersby, Founder and Executive Director of the Allo Hope Foundation. Together, they explore how red blood cell antibo
- PRQuidelOrtho to Participate in Upcoming June 2026 Investor ConferencesSAN DIEGO, May 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 46th Annual Growth Stock Conference, Tuesday, June 2, 2026Members of QuidelOrtho's management team will participate in a presentation at 12:20 p.m. ET / 9:20 a.m. PT.Jefferies Global Healthcare Conference, Wednesday, June 3, 2026Members of QuidelOrtho's management team will participate in a fireside
- INSIDERPresident and CEO Blaser Brian J. was granted 20,759 shares and covered exercise/tax liability with 10,252 shares, increasing direct ownership by 42% to 35,649 units (SEC Form 4) (withholding tax)4 - QuidelOrtho Corp (0001906324) (Issuer)
- SECSEC Form SD filed by QuidelOrtho CorporationSD - QuidelOrtho Corp (0001906324) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho CorporationSCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)
- ANALYSTQuidelOrtho downgraded by Jefferies with a new price targetJefferies downgraded QuidelOrtho from Buy to Hold and set a new price target of $12.50
- SECAmendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho CorporationSCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho CorporationSCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)
- SECSEC Form SCHEDULE 13G filed by QuidelOrtho CorporationSCHEDULE 13G - QuidelOrtho Corp (0001906324) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho CorporationSCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)
- SECQuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - QuidelOrtho Corp (0001906324) (Filer)
- PRQuidelOrtho Reports First Quarter 2026 Financial Results― LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics ―― Key Product Launches in U.S. and International Markets Expected to Drive Future Growth ―― Company Updates Full-Year 2026 Financial Guidance ― SAN DIEGO, May 5, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the first quarter ended March 29, 2026. Key First Quarter 2026 Results:(all comparisons are to the prior year period)Total revenue was $620
- INSIDEREVP Global Port. Mgmt & Mkting Hanson Bryan Michael was granted 1,459 shares and covered exercise/tax liability with 528 shares, increasing direct ownership by 30% to 4,070 units (SEC Form 4) (withholding obligation)4 - QuidelOrtho Corp (0001906324) (Issuer)
QDEL FAQ
6 questionsWhat does QuidelOrtho Corporation do?
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes...Where does QDEL stock trade?
QuidelOrtho Corporation (QDEL) is listed on NASDAQ.What sector and industry is QDEL in?
QuidelOrtho Corporation operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What are analysts saying about QDEL?
QuidelOrtho Corporation has had 8 recent analyst actions on file. The most recent action was from Jefferies: Hold with a $1250.00 price target on 2026-05-07. Recent price targets range from $1250.00 to $4400.00.What companies are similar to QDEL?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), ORKA (Oruka Therapeutics Inc.), NNNN (Anbio Biotechnology). Compare QDEL side-by-side with any of them on Quantisnow.How can I track QDEL on Quantisnow?
Quantisnow aggregates QuidelOrtho Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QDEL to receive live email and push alerts on every new disclosure.